These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31209624)

  • 1. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
    Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
    Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
    Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
    Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
    Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
    Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.
    Kobayashi E; Naito Y; Asano N; Maejima A; Endo M; Takahashi S; Megumi Y; Kawai A
    Jpn J Clin Oncol; 2019 Oct; 49(10):938-946. PubMed ID: 31365116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
    Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
    Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
    Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
    Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.
    Tsuchihashi K; Kusaba H; Yoshihiro T; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Imajima T; Shinohara Y; Ito M; Yamaga S; Tanoue K; Arimizu K; Ohmura H; Hanamura F; Yamaguchi K; Isobe T; Ariyama H; Nakashima Y; Akashi K; Baba E
    Sci Rep; 2020 Dec; 10(1):20896. PubMed ID: 33262403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study.
    Kawai A; Narahara H; Takahashi S; Nakamura T; Kobayashi H; Megumi Y; Matsuoka T; Kobayashi E
    BMC Cancer; 2022 May; 22(1):528. PubMed ID: 35546669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
    López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
    Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
    Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.
    Haddox CL; Nathenson MJ; Mazzola E; Lin JR; Baginska J; Nau A; Weirather JL; Choy E; Marino-Enriquez A; Morgan JA; Cote GM; Merriam P; Wagner AJ; Sorger PK; Santagata S; George S
    Clin Cancer Res; 2024 Apr; 30(7):1281-1292. PubMed ID: 38236580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
    Emambux S; Italiano A
    Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
    Demetri GD; Schöffski P; Grignani G; Blay JY; Maki RG; Van Tine BA; Alcindor T; Jones RL; D'Adamo DR; Guo M; Chawla S
    J Clin Oncol; 2017 Oct; 35(30):3433-3439. PubMed ID: 28854066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
    Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
    Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.
    Seetharam M; Kolla KR; Chawla SP
    Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
    Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
    Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
    Nakamura T; Asanuma K; Hagi T; Sudo A
    Drug Des Devel Ther; 2020; 14():4215-4220. PubMed ID: 33116409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin.
    Kobayashi H; Okuma T; Okajima K; Ishibashi Y; Zhang L; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Goto T; Tanaka S
    J Orthop Sci; 2022 Jan; 27(1):222-228. PubMed ID: 33384219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
    Kawano S; Asano M; Adachi Y; Matsui J
    Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.